Sophia Abene

This week, individualized training in high-volume transplant care, reassuring data on aluminum vaccine safety, smarter antibiotic stewardship, and more.

Two deaths and eight infections in Italy highlight the need for enhanced surveillance, proactive vector control, and cross-border collaboration in Europe and beyond.

Epidemiologist Anders Peter Hviid leads research reassuring vaccine safety across autoimmune, allergic, and neurodevelopmental disorders.

Vinay Prasad’s, MD, MPH, short tenure marked by tough regulatory decisions and political pushback; the Trump administration has not yet named a successor for the CBER director role.

Ep 2, Part 1 of 4: How infectious diseases may fuel global instability in a conversation with psychiatrist Robert Bransfield, MD.

Global modeling identifies vertical transmission burden and underscores need for maternal screening policies.

First representative data highlight regional and demographic variations, underscoring the need for enhanced vaccination and targeted interventions.

This week, AI speeds antibiotic discovery, Temple’s ID team celebrates tradition, EDs boost Hep C detection, thimerosal exits flu shots, and the pandemic’s silent toll on brain health emerges.

A long-acting HIV-1 capsid inhibitor demonstrates over 99% efficacy, paving the way for expanded access to adults and adolescents across the EU and low-income countries.

At ASM Microbe 2025, Pelumi Oladipo discusses E marmotae’s reduced motility, misidentification as E coli, and the diagnostic tools closing the gap.

New research reveals accelerated brain aging in healthy adults during the COVID-19 pandemic, highlighting broader neurological and social effects.

Lin Zhu explains why testing alone will not achieve HCV elimination without better access and integrated care.

CDC reports 11 people sick across 10 states with Salmonella linked to frozen sprouted beans causing diarrhea, fever, and severe illness in vulnerable groups.

Presented at ASM Microbe, Pelumi Oladipo's study identifies the first North American human case of E marmotae infection and introduces methods to improve species-level diagnosis.

Jason Haukoos, MD, on how the DETECT Hep C trial leverages 24/7 emergency care to reach vulnerable patients.

Edward Weinstein, MD of Pfizer, says longer courses may benefit severely immunocompromised patients, even without major gains in viral suppression.

This week, the first US study screening hepatitis B and D concurrently found that 2.2% of HBV-positive samples had HDV antibodies, the FDA approved GSK’s Shingrix, and more.

Luisa M Stamm, MD, PhD, further discusses MK-8527 and islatravir-based regimens in HIV research.

New evidence-based recommendations prioritize timely, targeted therapy and a symptom-focused classification to optimize treatment outcomes and antimicrobial stewardship.

At IAS 2025, ViiV’s Jean van Wyk, MBChB, MFPM, shares how real-world data and patient priorities are guiding a new era of HIV care.

New format eliminates reconstitution step, offering greater convenience for providers and supporting expanded access for at-risk adults.

New research finds no link between aluminum in vaccines and autism, asthma, or other health conditions, strengthening the case for vaccine safety.

Jason Haukoos, MD, MSc, FACEP, shares the decade-long journey behind the DETECT Hep C trial and why emergency departments are key to implementing Centers for Disease Control and Prevention screening guidelines.

Analysis by Carly Ching, PhD, reveals that global AMR policies overemphasize human health while neglecting farmer-focused messaging that could improve adoption and impact.

At IAS 2025, Luisa Stamm, MD, PhD, explains the NRTTI’s mechanism, study setup, and key data on HIV prevention efforts.

At IAS 2025, the VOLITION and OPERA study data show patient preference and real-world use of injectable CAB + RPV LA, informing the treatment strategy of ViiV CMO Jean van Wyk.

This week, a mother's struggle with C difficile during pregnancy, racial disparities in COVID-19 treatment, Supreme Court decision preserving access to HIV prevention, and more.

Quality improvement initiative at Henry Ford Health demonstrates streamlined workflow, rapid prior authorization, and low patient copayments; highlights opportunities for enhanced pharmacist involvement and education.

DETECT Hep C trial shows nontargeted testing in emergency departments outperforms risk-based screening, yet treatment follow-through remains low.

Carl Schmid on the US Supreme Court ruling, proposed Centers for Disease Control and Prevention cuts, stigma, and why equitable PrEP access, including new long-acting options, depends on more than insurance.